» Articles » PMID: 38798823

A New Approach to Prevent, Diagnose, and Treat Hepatitis B in Africa

Abstract

There are 82 million people living with hepatitis B (PLWHB) in the World Health Organization Africa region, where it is the main cause of liver disease. Effective vaccines have been available for over 40 years, yet there are 990,000 new infections annually, due to limited implementation of hepatitis B birth dose vaccination and antenatal tenofovir prophylaxis for highly viraemic women, which could eliminate mother-to-child transmission. Despite effective and cheap antiviral treatment which can suppress hepatitis B virus replication and reduce the risk of hepatocellular carcinoma (HCC), < 2% of PLWHB are diagnosed, and only 0.1% are treated. As a result, PLWHB are frequently diagnosed only when they have already developed decompensated cirrhosis and late-stage HCC, and consequently 80,000 hepatitis B-associated deaths occur each year. Major barriers include complex treatment guidelines which were derived from high-income settings, lack of affordable diagnostics, lack or insufficient domestic funding for hepatitis care, and limited healthcare infrastructure. Current treatment criteria may overlook patients at risk of cirrhosis and HCC. Therefore, expanded and simplified treatment criteria are needed. We advocate for decentralized community treatment programmes, adapted for low-resource and rural settings with limited laboratory infrastructure. We propose a strategy of treat-all except patients fulfilling criteria that suggest low risk of disease progression. Expanded treatment represents a financial challenge requiring concerted action from policy makers, industry, and international donor agencies. It is crucial to accelerate hepatitis B elimination plans, integrate hepatitis B care into existing healthcare programmes, and prioritize longitudinal and implementation research to improve care for PLWHB.

Citing Articles

Unveiling the Silent Crisis Amidst Tackling Hepatitis B in African Prisons - A Public Health Emergency.

Scott G, Aborode A, Adesola R, Hope C, Dipeolu O, Ajibade F Health Sci Rep. 2025; 8(3):e70543.

PMID: 40066240 PMC: 11892014. DOI: 10.1002/hsr2.70543.


Prevalence of overt and occult hepatitis B viral infection among pregnant women attending antenatal clinics in Edo state university teaching hospital Auchi, Nigeria.

Shuaib B, Momodu A, Ohenhen J, Umeche I, Muhibi M BMC Infect Dis. 2024; 24(1):1468.

PMID: 39731052 PMC: 11681770. DOI: 10.1186/s12879-024-10376-2.


Immune response to GeneVac-B (rDNA I.P. hepatitis B vaccine) in vaccinated persons with a standard schedule in Bobo-Dioulasso, Burkina Faso.

Ouattara N, Sanou A, Napon-Zongo D, Coulibaly A, Korogho S, Dera A IJID Reg. 2024; 13:100483.

PMID: 39639948 PMC: 11618024. DOI: 10.1016/j.ijregi.2024.100483.


Seroprevalence of viral hepatitis B and C infections among healthcare workers in Ethiopia: A systematic review and meta-analysis.

Girmay G, Bewket G, Amare A, Angelo A, Wondmagegn Y, Setegn A PLoS One. 2024; 19(11):e0312959.

PMID: 39509362 PMC: 11542802. DOI: 10.1371/journal.pone.0312959.


Epidemiology of hepatitis B virus infection among pregnant women in Africa: a systematic review and meta-analysis.

Wondmeneh T, Mekonnen A BMC Infect Dis. 2024; 24(1):921.

PMID: 39237884 PMC: 11375975. DOI: 10.1186/s12879-024-09839-3.


References
1.
Franklin S, Mouliom A, Sinkala E, Kanunga A, Helova A, Dionne-Odom J . Hepatitis B virus contact disclosure and testing in Lusaka, Zambia: a mixed-methods study. BMJ Open. 2018; 8(9):e022522. PMC: 6157559. DOI: 10.1136/bmjopen-2018-022522. View

2.
Younossi Z, Stepanova M, Janssen H, Agarwal K, Nguyen M, Gane E . Effects of Treatment of Chronic Hepatitis B Virus Infection on Patient-Reported Outcomes. Clin Gastroenterol Hepatol. 2018; 16(10):1641-1649.e6. DOI: 10.1016/j.cgh.2018.02.037. View

3.
Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson I . Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2012; 381(9865):468-75. DOI: 10.1016/S0140-6736(12)61425-1. View

4.
Tu T, Block J, Wang S, Cohen C, Douglas M . The Lived Experience of Chronic Hepatitis B: A Broader View of Its Impacts and Why We Need a Cure. Viruses. 2020; 12(5). PMC: 7290920. DOI: 10.3390/v12050515. View

5.
. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017; 67(2):370-398. DOI: 10.1016/j.jhep.2017.03.021. View